대화제약

067080KOSDAQ의약품 제조업

37.0 / 100

Reference Date: 2026-04-13

Financial Score9.5 / 40

News Sentiment12.5 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: PER raises overvaluation concerns, PBR raises overvaluation concerns. Declined 6.7% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Dae Hwa Pharmaceutical primarily engages in the manufacturing and sales of pharmaceuticals, medical devices, and raw materials, supplying a wide range of products such as antibiotics and pain relievers both domestically and internationally. The company has expanded its overseas markets through partnerships with German and Chinese firms and focuses on R&D investment for new drug development.

Number of Employees

369people

Average Salary

48.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

148.94Industry Average 14.800.0Point

10.1x industry avg (risky)

PBR

3.29Industry Average 1.040.0Point

3.2x industry avg (risky)

ROE

3.00Industry Average 4.422.5Point

Below industry avg

Debt Ratio

12.94Industry Average 11.982.0Point

Higher than industry avg (caution)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲0.7% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲94.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 1.1% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50

Neutral
대화제약, 지난해 영업익 32억원…전년비 52,8%↓
대화제약은 지난해 영업이익이 32억원으로 전년 대비 52.8% 감소했으나, 당기순이익은 180.7% 증가했다.

Detailed Momentum

52-week position1.0Point

Near 52w low (12%, downtrend)

Current 14,000Won52-week high 23,30052-week low 12,650

1-month return2.0Point

1m -6.67% (slight drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0

Neutral기업가치제고계획(자율공시)2026-04-01
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-04-01
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-27
Neutral사업보고서 (2025.12)2026-03-23
Neutral감사보고서제출2026-03-23